当前位置: 首页 >> 检索结果
4682. SER-109, an Oral Microbiome Therapy for Recurrent Clostridioides difficile Infection.
作者: Paul Feuerstadt.;Thomas J Louie.;Bret Lashner.;Elaine E L Wang.;Liyang Diao.;Jessica A Bryant.;Matthew Sims.;Colleen S Kraft.;Stuart H Cohen.;Charles S Berenson.;Louis Y Korman.;Christopher B Ford.;Kevin D Litcofsky.;Mary-Jane Lombardo.;Jennifer R Wortman.;Henry Wu.;John G Auniņš.;Christopher W J McChalicher.;Jonathan A Winkler.;Barbara H McGovern.;Michele Trucksis.;Matthew R Henn.;Lisa von Moltke.
来源: N Engl J Med. 2022年386卷3期220-229页
Current therapies for recurrent Clostridioides difficile infection do not address the disrupted microbiome, which supports C. difficile spore germination into toxin-producing bacteria. SER-109 is an investigational microbiome therapeutic composed of purified Firmicutes spores for the treatment of recurrent C. difficile infection.
4683. Randomized Trial of Closed-Loop Control in Very Young Children with Type 1 Diabetes.
作者: Julia Ware.;Janet M Allen.;Charlotte K Boughton.;Malgorzata E Wilinska.;Sara Hartnell.;Ajay Thankamony.;Carine de Beaufort.;Ulrike Schierloh.;Elke Fröhlich-Reiterer.;Julia K Mader.;Thomas M Kapellen.;Birgit Rami-Merhar.;Martin Tauschmann.;Katrin Nagl.;Sabine E Hofer.;Fiona M Campbell.;James Yong.;Korey K Hood.;Julia Lawton.;Stephane Roze.;Judy Sibayan.;Laura E Bocchino.;Craig Kollman.;Roman Hovorka.; .
来源: N Engl J Med. 2022年386卷3期209-219页
The possible advantage of hybrid closed-loop therapy (i.e., artificial pancreas) over sensor-augmented pump therapy in very young children with type 1 diabetes is unclear.
4684. Immunogenicity and Reactogenicity of Vaccine Boosters after Ad26.COV2.S Priming.
作者: Roos S G Sablerolles.;Wim J R Rietdijk.;Abraham Goorhuis.;Douwe F Postma.;Leo G Visser.;Daryl Geers.;Katharina S Schmitz.;Hannah M Garcia Garrido.;Marion P G Koopmans.;Virgil A S H Dalm.;Neeltje A Kootstra.;Anke L W Huckriede.;Melvin Lafeber.;Debbie van Baarle.;Corine H GeurtsvanKessel.;Rory D de Vries.;P Hugo M van der Kuy.; .
来源: N Engl J Med. 2022年386卷10期951-963页
The Ad26.COV2.S vaccine, which was approved as a single-shot immunization regimen, has been shown to be effective against severe coronavirus disease 2019. However, this vaccine induces lower severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein (S)-specific antibody levels than those induced by messenger RNA (mRNA)-based vaccines. The immunogenicity and reactogenicity of a homologous or heterologous booster in persons who have received an Ad26.COV2.S priming dose are unclear.
4689. Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer.
作者: Vicky Makker.;Nicoletta Colombo.;Antonio Casado Herráez.;Alessandro D Santin.;Emeline Colomba.;David S Miller.;Keiichi Fujiwara.;Sandro Pignata.;Sally Baron-Hay.;Isabelle Ray-Coquard.;Ronnie Shapira-Frommer.;Kimio Ushijima.;Jun Sakata.;Kan Yonemori.;Yong Man Kim.;Eva M Guerra.;Ulus A Sanli.;Mary M McCormack.;Alan D Smith.;Stephen Keefe.;Steven Bird.;Lea Dutta.;Robert J Orlowski.;Domenica Lorusso.; .
来源: N Engl J Med. 2022年386卷5期437-448页
Standard therapy for advanced endometrial cancer after failure of platinum-based chemotherapy remains unclear.
4690. Balanced Multielectrolyte Solution versus Saline in Critically Ill Adults.
作者: Simon Finfer.;Sharon Micallef.;Naomi Hammond.;Leanlove Navarra.;Rinaldo Bellomo.;Laurent Billot.;Anthony Delaney.;Martin Gallagher.;David Gattas.;Qiang Li.;Diane Mackle.;Jayanthi Mysore.;Manoj Saxena.;Colman Taylor.;Paul Young.;John Myburgh.; .
来源: N Engl J Med. 2022年386卷9期815-826页
Whether the use of balanced multielectrolyte solution (BMES) in preference to 0.9% sodium chloride solution (saline) in critically ill patients reduces the risk of acute kidney injury or death is uncertain.
4691. Plasma Neutralization of the SARS-CoV-2 Omicron Variant.
作者: Fabian Schmidt.;Frauke Muecksch.;Yiska Weisblum.;Justin Da Silva.;Eva Bednarski.;Alice Cho.;Zijun Wang.;Christian Gaebler.;Marina Caskey.;Michel C Nussenzweig.;Theodora Hatziioannou.;Paul D Bieniasz.
来源: N Engl J Med. 2022年386卷6期599-601页 4694. Combating Structural Inequities - Diversity, Equity, and Inclusion in Clinical and Translational Research.
作者: L Ebony Boulware.;Giselle Corbie.;Sergio Aguilar-Gaxiola.;Consuelo H Wilkins.;Raquel Ruiz.;Alfred Vitale.;Leonard E Egede.
来源: N Engl J Med. 2022年386卷3期201-203页 4697. Effectiveness of BNT162b2 Vaccine against Critical Covid-19 in Adolescents.
作者: Samantha M Olson.;Margaret M Newhams.;Natasha B Halasa.;Ashley M Price.;Julie A Boom.;Leila C Sahni.;Pia S Pannaraj.;Katherine Irby.;Tracie C Walker.;Stephanie P Schwartz.;Aline B Maddux.;Elizabeth H Mack.;Tamara T Bradford.;Jennifer E Schuster.;Ryan A Nofziger.;Melissa A Cameron.;Kathleen Chiotos.;Melissa L Cullimore.;Shira J Gertz.;Emily R Levy.;Michele Kong.;Natalie Z Cvijanovich.;Mary A Staat.;Satoshi Kamidani.;Brandon M Chatani.;Samina S Bhumbra.;Katherine E Bline.;Mary G Gaspers.;Charlotte V Hobbs.;Sabrina M Heidemann.;Mia Maamari.;Heidi R Flori.;Janet R Hume.;Matt S Zinter.;Kelly N Michelson.;Laura D Zambrano.;Angela P Campbell.;Manish M Patel.;Adrienne G Randolph.; .
来源: N Engl J Med. 2022年386卷8期713-723页
The increasing incidence of pediatric hospitalizations associated with coronavirus disease 2019 (Covid-19) caused by the B.1.617.2 (delta) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the United States has offered an opportunity to assess the real-world effectiveness of the BNT162b2 messenger RNA vaccine in adolescents between 12 and 18 years of age.
4699. Duration of Protection against Mild and Severe Disease by Covid-19 Vaccines.
作者: Nick Andrews.;Elise Tessier.;Julia Stowe.;Charlotte Gower.;Freja Kirsebom.;Ruth Simmons.;Eileen Gallagher.;Simon Thelwall.;Natalie Groves.;Gavin Dabrera.;Richard Myers.;Colin N J Campbell.;Gayatri Amirthalingam.;Matt Edmunds.;Maria Zambon.;Kevin Brown.;Susan Hopkins.;Meera Chand.;Shamez N Ladhani.;Mary Ramsay.;Jamie Lopez Bernal.
来源: N Engl J Med. 2022年386卷4期340-350页
Vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (Covid-19), have been used since December 2020 in the United Kingdom. Real-world data have shown the vaccines to be highly effective against Covid-19 and related severe disease and death. Vaccine effectiveness may wane over time since the receipt of the second dose of the ChAdOx1-S (ChAdOx1 nCoV-19) and BNT162b2 vaccines.
|